External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Rheumatology EULAR 2026
Roche and Genentech at

EULAR 2026

June 03 - June 06
London, UK
eular.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
08:30 AM
Duration 60mins London, UK
The Impact of Obinutuzumab on Remission and Low Disease Activity in Active Systemic Lupus Erythematosus: Additional Results of the Phase III ALLEGORY Trial
Richard A. Furie, Maria Dall’Era, Edward M. Vital, Jay P. Garg, Adolfina E. Zuta Santillán, Mittermayer B. Santiago, Stella Botha, Piotr Leszczyński, Viviane Angelina de Souza, Zahir Amoura, Maria Antonietta D’Agostino, Sunil Kumar, Julie Rae, Huiyan A. Mao, Felix Erblang, Oliver Meier, Justine C. Maller, Anca D. Askanase
Rheumatology | Systemic Lupus Erythematosus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins London, UK
Obinutuzumab in Systemic Lupus Erythematosus: A Secondary Safety Analysis of Infusion-Related Reactions, Infections, Neutropenia and Immunoglobulin G in the Phase III ALLEGORY Trial
Anca D. Askanase, Edward M. Vital, Zahir Amoura, Grzegorz Rozumek, José Maria Álvaro Gracia, Rodrigo de Oliveira, Felix Erblang, Olga Mitrofanova, Peiqing Yu, Oliver Meier, Justine C. Maller, Jay P. Garg, Maria Dall’Era, Richard A. Furie
Rheumatology | Systemic Lupus Erythematosus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins London, UK
Obinutuzumab Demonstrates Consistent Efficacy in Lupus Nephritis Independent of Baseline Type 1 Interferon Gene Signature: Post-Hoc Exploratory Analyses of the Phase III REGENCY Trial
Edward M. Vital, Harini Raghu, Jason Hackney, William F. Pendergraft III, Richard A. Furie, Brad H. Rovin
Rheumatology - Nephrology | Lupus Nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:25 AM
Duration 10mins London, UK
Obinutuzumab Induces Histological Remission and Deep Kidney Parenchymal B-Cell Depletion in Patients With Lupus Nephritis: Exploratory Analyses of the Phase III REGENCY Trial
Richard A. Furie, Brad H. Rovin, Elsa Martins, Cary D. Austin, Harini Raghu, Caleb Chan, Patrick S. Chang, Jay P. Garg, Valeria Alberton, Mittermayer B. Santiago, Gustavo Aroca-Martínez, Fedra I. Palazuelos, Teresa Baczkowska, Jose Alfaro, Jorge Ravelo-Hernández, Luis F. Pinto, Eduardo H. Albiero, Christopher Larsen, Bongin Yoo, Jennifer Pulley, Andrew Thorley, Thomas Schindler, Theodore A. Omachi, William F. Pendergraft, Ana Malvar
Rheumatology - Nephrology | Lupus Nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:00 PM
Duration 60mins London, UK
ALLEGORY Phase III Trial in Systemic Lupus Erythematosus: Pharmacodynamic Effects of Obinutuzumab
Richard A. Furie, Edward M. Vital, Julie Rae, Huiyan A. Mao, Oliver Meier, Justine C. Maller, Jay P. Garg, Harini Raghu, Maria Dall’Era
Rheumatology | Systemic Lupus Erythematosus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.